The novel curcumin analogue AKT-100 targets both mutant p53 and STAT3 in gynecologic cancer cells
Geneva L. Williams, Lane E. Smith, Jamie L. Padilla, Alexander Goss, Daisy Belmares-Ortega, Xiangxiang Wu, Jennifer Daw, Sumegha Mitra, Prakash G. Jagtap, Josh K. Monts, Jun‐yong Choe, Kimberly Kay Leslie
This paper develops AKT-100, a curcumin analogue that targets mutant p53 and STAT3 in gynecologic cancer cells, showing cytotoxicity and synergy with existing therapies.
bioRxiv · Oct 6, 2025 · PreprintCancer Biology